Helicia Paz-Chang

Helicia Paz-Chang is an accomplished scientist with extensive experience in translational sciences and bioanalysis. Currently serving as the Director of Translational Sciences Bioanalysis at AstraZeneca since January 2025, Helicia previously held the position of Principal Scientist at Neogene Therapeutics from January 2021 to January 2025 and led research teams at T-Cure Biosciences Inc. and UCLA. Work at T-Cure Biosciences involved leading the discovery of candidate Class I and Class II TCRs using the proprietary iSORT platform. At UCLA, Helicia researched genetic T cell modifications in adoptive cell therapy and their relationship with drug resistance in melanoma. Earlier experience includes a postdoctoral fellowship at Children's Hospital Los Angeles, focusing on pre-B acute lymphoblastic leukemia and its survival mechanisms. Helicia holds a PhD in Molecular Biology from UCLA and a BS in Biology from Duke University.